Holen Sie sich die Stockscreener-App
6.52
4.96%
-0.34
Schlusskurs vom Vortag:
$6.86
Offen:
$6.88
24-Stunden-Volumen:
67,004
Relative Volume:
0.73
Marktkapitalisierung:
$726.91M
Einnahmen:
$117.05M
Nettoeinkommen (Verlust:
$-3.71M
KGV:
-83.70
EPS:
-0.0779
Netto-Cashflow:
$1.67M
1W Leistung:
-11.17%
1M Leistung:
+9.58%
6M Leistung:
-11.89%
1J Leistung:
-16.52%
1-Tages-Spanne:
$6.50
$6.885
1-Wochen-Bereich:
$6.50
$7.47
52-Wochen-Spanne:
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(858) 284-0115
Adresse
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.52 | 726.91M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus - ad-hoc-news.de
GYREGyre Therapeutics Inc Options - Finviz
Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95 - Stock Titan
Director Dan Weng receives 40,000-share option grant at GYRE (NASDAQ: GYRE) - Stock Titan
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
US High Growth Tech Stocks to Watch - simplywall.st
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark - marketscreener.com
GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Defensive Index - marketscreener.com
Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
Price to book forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Enterprise value to EBITDA forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Enterprise value to EBIT forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView
Price to earnings forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView
Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE) - TradingView
Enterprise value to revenue forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to book forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
GYRE Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to sales forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to sales forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition - TipRanks
Gyre Therapeutics | S-3: Registration statement for specified transactions by certain issuers - Moomoo
Form S-3 Gyre Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Gyre Therapeutics (NASDAQ: GYRE) registers 30.2M resale shares post-merger - Stock Titan
Gyre Therapeutics (GYRE) COO trades 11,000 shares, retains 700,000 - Stock Titan
GYRE Q1 2026 Earnings: Narrowed Loss Surpasses Expectations, Shares RiseProfit Recovery Report - dars.gov.et
Gyre Therapeutics StockLong-term business model and pipeline focus - AD HOC NEWS
Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Institutional Confidence - TradingKey
Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gyre Therapeutics Shareholders Approve Directors and Governance Measures - The Globe and Mail
Gyre Therapeutics stockholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
Gyre Therapeutics stockholders approve all proposals at annual meeting - Investing.com
Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion - Stock Titan
Gyre Therapeutics, Inc. Files 8-K with SEC: Company Information, Address, and NASDAQ Ticker GYRE - Minichart
Gyre COO Ye Weiguo sells $17,276 in company stock By Investing.com - Investing.com Canada
Gyre COO Ye Weiguo sells $17,276 in company stock - Investing.com
Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options - Stock Titan
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
GYRE Q1 2026 Earnings: EPS Surprises to the Upside, Revenue Not Reported, Stock SlipsForward EPS Estimate - newsline.com
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):